Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511296 | 0.89 | MAPT (0.42) | MAPTHTTHSD17B10NPSR1KDM4E | |
| SCHEMBL20511291 | 0.82 | MAPT (0.47) | MAPTHTTHSD17B10NPSR1KDM4E | |
| SCHEMBL13263672 | 0.80 | KDM4E (0.68) | MAPTHTTHSD17B10NPSR1KDM4E | |
| SCHEMBL24378542 | 0.78 | CYP1A2 (0.42) | MAPTHSD17B10NPSR1KDM4EHPGD | |
| SCHEMBL27009150 | 0.78 | CYP1A2 (0.42) | MAPTHSD17B10NPSR1KDM4EHPGD | |
| SCHEMBL21799207 | 0.76 | KDM4E (0.56) | MAPTHTTKDM4EHPGDMAPK1 | |
| SCHEMBL21799206 | 0.76 | KDM4E (0.56) | MAPTHTTKDM4EHPGDMAPK1 | |
| SCHEMBL24099572 | 0.75 | HTT (0.43) | MAPTHTTHSD17B10NPSR1KDM4E | |
| SCHEMBL20511355 | 0.75 | TDP1 (0.49) | MAPTLMNASMN1; SMN2PDE10ACYP1A2 | |
| SCHEMBL24099728 | 0.75 | HTT (0.47) | MAPTHTTHSD17B10NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294536-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKSCI INC. (CA) | 2024-05-21 | — | — | US | disclosed |
| US-20210323969-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2021-10-21 | — | — | US | disclosed |
| US-20210323969-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2021-10-21 | — | — | US | disclosed |
| US-11066410-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | 3100 CENTRAL EXPRESSWAY LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066410-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | 3100 CENTRAL EXPRESSWAY LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200079780-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | NANOSYN, INC. | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKFYVE, PIP4K2B, PIP4K2A | MAPT 2023/4885HTT 2855/4885HSD17B10 3156/4885 |
| US-20210323969-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIP4K2A | MAPT 2023/4885HTT 2855/4885HSD17B10 3156/4885 |
| US-11066410-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKFYVE, PIP4K2B, PIP4K2A | MAPT 2023/4885HTT 2855/4885HSD17B10 3156/4885 |
| US-20200079780-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIP4K2A | MAPT 2023/4885HTT 2855/4885HSD17B10 3156/4885 |
| US-20240294536-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIK3CA | MAPT 3840/4885HTT 3940/4885HSD17B10 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.